Principia taps Series A tranche to arm warheads for covalent drug IND
This article was originally published in Scrip
Principia Biopharma will use $12.5 million from the second tranche of a tiered Series A round totaling $36.3 million to file an investigational new drug (IND) application with the US FDA in 2013 for its first covalent drug.
You may also be interested in...
The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.